Developing Remelix
An innovative novel intra-joint injection with rAmelX for treating joints with injured cartilage and ligaments
About us
Our Mission
Planeeria is an emerging R&D start-up focused on the development of innovative regeneration products in orthopedics.
Planeeria has developed Remelix, based on recombinant human amelogenin technology to treat injured cartilage and ligaments.
At Planeeria, we are committed to advancing orthopedic regeneration products that improve patient outcomes and enhance quality of life. Our mission is to develop innovative solutions for joint regeneration, focusing on our groundbreaking Remelix based on our formulations with the amelogenin protein active ingredient.
Our vision is to be the trusted partner for healthcare professionals worldwide, providing state-of-the-art technology and support to tackle the challenges of cartilage and ligament injuries. Our goal for Remelix is to become a leading shelf product as an alternative to PRP and stem cell therapies. We strive to maintain excellence in research, development, and customer service, ensuring that our solutions make a tangible difference in the field of orthopedics.
Remelix used in ankle surgey
Remelix is the only treatment for the regeneration of OCDs and injured ligaments
Our Journey
Founded in 2018 with a passion for innovation, Planeeria has evolved into a leader in amelogenin based products with a new approach to orthopedic regenerative solutions. Our journey began with the development of Recombigain, the dental version by Prudnetix Ltd followed by Remelix, a pioneering intra-joint injection.
How does it work?
Amelogenins recruit mesenchymal stem cells and pericytes to the injured site which subsequently differentiate to regenerate the tissueshe product serves as a physical scaffold with a biologically active component: The amelogenin nanospheres play an extra-cellular structural role in the development of various tissues
Our solution
A novel, sterile, pure injectable biological therapy for regeneration and healing of articular (hyaline) cartilage and ligaments in traumatized joints.
Registration path: class III sterile medical device with a biological substance (MDR 2017/745, FDA 21-CFR)
Produced using genetic recombination technology.
The founders and team
stablished by chemist entrepreneurs with a 25-year track record of founding successful pharmaceutical companies.
At Planeeria, we believe that innovation stems from collaboration. Our team is comprised of dedicated professionals at the forefront of developing medical device technologies for healthcare professionals